MedMira Inc (MedMira) develops, manufactures and markets rapid diagnostics. It develops rapid diagnostics by Rapid Vertical Flow (RVF) technology. The company offers rapid testing solutions in the areas of HIV, H. pylori, hepatitis, syphilis, RVF toolkits and other infectious and sexually transmitted diseases. MedMira offers an RVF toolkit that facilitates the quality of disease diagnosis and management. The company serves hospitals, point-of-care facilities, laboratories, researchers, biotech companies, governments and public health agencies. MedMira markets its products through a network of distributors and business development partners. The company operates through its subsidiaries in Canada, the US and Switzerland. MedMira is headquartered in Halifax, Nova Scotia, Canada.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company MedMira Inc
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design, trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Table of Contents
- MedMira Inc Company Overview
- MedMira Inc Company Snapshot
- MedMira Inc Pipeline Products and Ongoing Clinical Trials Overview
- MedMira Inc - Pipeline Analysis Overview
- MedMira Inc - Key Facts
- MedMira Inc - Major Products and Services
- MedMira Inc Pipeline Products by Development Stage
- MedMira Inc Ongoing Clinical Trials by Trial Status
- MedMira Inc Pipeline Products Overview
- HH Marker Chronic Disease Monitoring Test - Breast Cancer CA-15-3
- HH Marker Chronic Disease Monitoring Test - Breast Cancer CA-15-3 Product Overview
- HH Marker Chronic Disease Monitoring Test - Cardiac Multiplex B
- HH Marker Chronic Disease Monitoring Test - Cardiac Multiplex B Product Overview
- MedDuo Dual HIV Ab/Ag Test
- MedDuo Dual HIV Ab/Ag Test Product Overview
- MedDuo Dual Total Hepatitis B Screen Test
- MedDuo Dual Total Hepatitis B Screen Test Product Overview
- Miriad Rapid Vertical Flow Assay Tool Kit - Trichomonas Vaginalis
- Miriad Rapid Vertical Flow Assay Tool Kit - Trichomonas Vaginalis Product Overview
- Multiplo Rapid HBV/HIV/HCV/TP Assay
- Multiplo Rapid HBV/HIV/HCV/TP Assay Product Overview
- Reveal HBsAg Rapid Test
- Reveal HBsAg Rapid Test Product Overview
- Reveal TP
- Reveal TP Product Overview
- Reveal TP Clinical Trial
- Reveal TSH Single Test
- Reveal TSH Single Test Product Overview
- REVEALCOVID-19 Nab-Y [Nab-Y] Neutralizing Test
- REVEALCOVID-19 Nab-Y [Nab-Y] Neutralizing Test Product Overview
- REVEALCOVID-19 PLUS Total Antibody Test
- REVEALCOVID-19 PLUS Total Antibody Test Product Overview
- REVEALCOVID-19 Total Antibody Test
- REVEALCOVID-19 Total Antibody Test Product Overview
- VYRA CoV-2 Antigen Test
- VYRA CoV-2 Antigen Test Product Overview
- VYRA CoV2Flu Test
- VYRA CoV2Flu Test Product Overview
- VYRA TriDemic
- VYRA TriDemic Product Overview
- MedMira Inc - Key Competitors
- MedMira Inc - Key Employees
- MedMira Inc - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Recent Developments
- MedMira Inc, Recent Developments
- Feb 25, 2025: MedMira Announces Exclusive Distribution Agreement with Trimedic for Canada
- Jan 21, 2025: MedMira Receives Investigational Testing Authorizations for Multiplo TP/HIV Self-Test and Non-Professional Use Applications
- Jan 14, 2025: MedMira Receives Health Canada Approval for Its Reveal(R) G4 Rapid HIV-1/2 Test for Point-of-Care Use
- Jan 09, 2025: MedMira Receives Investigational Testing Authorization for its Multiplo(R) Complete Syphilis (TP/nTP) Antibody Test
- Dec 26, 2024: Health Canada approves MedMira's rapid test for HIV and syphilis
- Nov 28, 2024: MedMira Reports FY2024 Fourth Quarter and Year End Financial Results
- Mar 13, 2024: MedMira Receives Canadian Patent for its Unique Quantitative Diagnostic System
- Dec 26, 2023: MedMira Receives 510(k) Clearance for Reveal G4 Rapid HIV-1/2 Antibody Test
- Feb 20, 2023: Maternova and MedMira enter distribution agreement to market rapid diagnostics for HIV, syphilis and hepatitis
- Jan 11, 2023: MedMira receives CE mark for its VYRA CoV2Flu Antigen Test
- Appendix
- Methodology
- About the Analyst
- Contact the Publisher
- Disclaimer
- MedMira Inc Pipeline Products and Ongoing Clinical Trials Overview
- MedMira Inc Pipeline Products by Equipment Type
- MedMira Inc Pipeline Products by Indication
- MedMira Inc Ongoing Clinical Trials by Trial Status
- MedMira Inc, Key Facts
- MedMira Inc, Major Products and Services
- MedMira Inc Number of Pipeline Products by Development Stage
- MedMira Inc Pipeline Products Summary by Development Stage
- MedMira Inc Ongoing Clinical Trials by Trial Status
- MedMira Inc Ongoing Clinical Trials Summary
- HH Marker Chronic Disease Monitoring Test - Breast Cancer CA-15-3 - Product Status
- HH Marker Chronic Disease Monitoring Test - Breast Cancer CA-15-3 - Product Description
- HH Marker Chronic Disease Monitoring Test - Cardiac Multiplex B - Product Status
- HH Marker Chronic Disease Monitoring Test - Cardiac Multiplex B - Product Description
- MedDuo Dual HIV Ab/Ag Test - Product Status
- MedDuo Dual HIV Ab/Ag Test - Product Description
- MedDuo Dual Total Hepatitis B Screen Test - Product Status
- MedDuo Dual Total Hepatitis B Screen Test - Product Description
- Miriad Rapid Vertical Flow Assay Tool Kit - Trichomonas Vaginalis - Product Status
- Miriad Rapid Vertical Flow Assay Tool Kit - Trichomonas Vaginalis - Product Description
- Multiplo Rapid HBV/HIV/HCV/TP Assay - Product Status
- Multiplo Rapid HBV/HIV/HCV/TP Assay - Product Description
- Reveal HBsAg Rapid Test - Product Status
- Reveal HBsAg Rapid Test - Product Description
- Reveal TP - Product Status
- Reveal TP - Product Description
- Reveal TP - Evaluation of the Sensitivity, Specificity, And Utility of the Reveal TP (Syphilis) Antibody POCT to Diagnose Infectious Syphilis in Participants Attending the BCCDC's STI Clinic in Vancouver, BC
- Reveal TP - Syphilis and HIV Point of Care Testing (POCT) to Improve Access to Testing Among Inner City, Remote, Rural and Hard to Reach Populations in Saskatchewan
- Reveal TSH Single Test - Product Status
- Reveal TSH Single Test - Product Description
- REVEALCOVID-19 Nab-Y [Nab-Y] Neutralizing Test - Product Status
- REVEALCOVID-19 Nab-Y [Nab-Y] Neutralizing Test - Product Description
- REVEALCOVID-19 PLUS Total Antibody Test - Product Status
- REVEALCOVID-19 PLUS Total Antibody Test - Product Description
- REVEALCOVID-19 Total Antibody Test - Product Status
- REVEALCOVID-19 Total Antibody Test - Product Description
- VYRA CoV-2 Antigen Test - Product Status
- VYRA CoV-2 Antigen Test - Product Description
- VYRA CoV2Flu Test - Product Status
- VYRA CoV2Flu Test - Product Description
- VYRA TriDemic - Product Status
- VYRA TriDemic - Product Description
- MedMira Inc, Key Employees
- MedMira Inc, Subsidiaries
- Glossary
- MedMira Inc Pipeline Products by Equipment Type
- MedMira Inc Pipeline Products by Development Stage
- MedMira Inc Ongoing Clinical Trials by Trial Status
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- ZoomMed Inc
- BlueRush Inc
- SQI Diagnostics Inc
- Pyng Medical Corp
- AioCare
